Elizabeth A. Mullen MD
Associate Professor of Pediatrics, Dana-Farber Cancer Institute
Join to view full profile
450 Brookline AvenueBoston, MA 02215
Phone+1 617-632-1938
Fax+1 617-632-4811
Dr. Mullen is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Elizabeth Mullen is a specialist in Pediatric Hematology & Oncology based in Boston, MA. Dr. Mullen graduated from Yale School of Medicine in 1992 and completed a residency in Pediatrics and a fellowship in Pediatric Hematology/Oncology at Boston Children’s Hospital/Boston Medical Center by 1998. Dr. Mullen has several publications, including work on Wilms Tumor and malignant rhabdoid tumors, and has contributed to clinical guidelines and significant oncological research. Dr. Mullen is also involved in clinical trials focused on biomarkers in pediatric tumors and treatment protocols for Wilms Tumor.
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1995 - 1998- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1992 - 1995
Yale School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1995 - 2028
CT State Medical License 2022 - 2027
ME State Medical License 2022 - 2027
VT State Medical License 2023 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2019-2026
- Exceptional Women in Medicine Castle Connolly, 2019-2026
- Top Doctor Boston Magazine, 2018-2026
Clinical Trials
- Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Start of enrollment: 2006 Nov 06
- Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors
- Biomarkers in Urine Samples From Patients With Wilms Tumor
Publications & Presentations
PubMed
- Feasibility of Real-Time Central Risk Assignment for Children's Oncology Group Pediatric Renal Tumor Trials.Elizabeth A Mullen, Lindsay A Renfro, Peter F Ehrlich, Geetika Khanna, Amy L Treece
Pediatric Blood & Cancer. 2026-11-01 - Bilateral Wilms Tumor: Multi-institutional analysis of nephron-sparing surgery at centers with focused wilms tumor expertise.Andrew J Murphy, N Valeska Halstead, Brett Wiesen, Jordan A Coggins, Mary Houston
Journal of Pediatric Surgery. 2026-10-16 - The Impact of Older Age at Diagnosis on Wilms Tumor Characteristics and Patient Outcomes: A Children's Oncology Group Study.Michael V Ortiz, Lindsay A Renfro, Ian C Tfirn, Nicholas G Cost, Elisabeth T Tracy
Journal of the National Comprehensive Cancer Network. 2026-10-08
Press Mentions
New NCCN Guidelines Analyze Evidence for Cancer Type Found Almost Exclusively in ChildrenFebruary 17th, 2021
More Than 110 Dana-Farber Affiliated Faculty Named as 2021 Top Doctors in Boston MagazineJanuary 5th, 2021- Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children with Solid TumorsJuly 5th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: